Table 3A.
Factors associated with fibrosis—univariable analysis
| Factor | Progression(n=79) | No Progression(n=69) | Hazard Ratio(95% CI) | p value |
|---|---|---|---|---|
| Underlying diagnosis (HCV vs NASH) | 68 (86.1) | 27 (39.1) | 2.1 (1.1, 3.9) | 0.025 |
| Male | 67 (84.8) | 45 (65.2) | 1.6 (0.86, 3.0) | 0.14 |
| Non-Caucasian | 22 (27.9) | 7 (10.1) | 1.6 (0.95, 2.6) | 0.078 |
| Age | 55.0 (49.0, 58.0) | 57.0 (52.0, 62.3) | 0.98 (0.95, 1.02) | 0.31 |
| Triglyceride | 137.0 (92.0, 200.0) | 174.0 (125.0, 224.0) | 0.998 (0.994, 1.001) | 0.11 |
| HDL | 43.0 (35.0, 55.0) | 43.0 (35.0, 51.0) | 1.01 (0.99, 1.02) | 0.21 |
| Tacrolimus | 68 (86.1) | 60 (87.0) | 0.95 (0.50, 1.8) | 0.87 |
| Cyclosporine | 8 (10.1) | 5 (7.3) | 1.1 (0.54, 2.4) | 0.73 |
| Mycophenolate mofetil | 25 (31.7) | 28 (40.6) | 1.1 (0.70, 1.8) | 0.6 |
| Diabetes post-OLT | 49 (62.0) | 38 (55.1) | 1.9 (1.2, 3.0) | 0.008 |
| Hypertension post-OLT | 51 (64.6) | 38 (55.1) | 1.6 (1.01, 2.6) | 0.044 |
| BMI @1 yr post-OLT | 27.6 (24.0, 31.2) | 29.0 (25.1, 32.9) | 0.96 (0.92, 1.01) | 0.12 |
| MS @1 yr post-OLT | 40 (59.7) | 25 (44.6) | 1.8 (1.1, 3.0) | 0.019 |
| Acute cellular rejection | 39 (49.4) | 26 (37.7) | 1.3 (0.84, 2.0) | 0.24 |
| Steroids | 28 (37.3) | 6 (8.7) | 1.9 (1.2, 3.0) | 0.009 |
Values are presented as n(%) or median (25%ile, 75%ile)